<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04554797</url>
  </required_header>
  <id_info>
    <org_study_id>RE-HIBER</org_study_id>
    <nct_id>NCT04554797</nct_id>
  </id_info>
  <brief_title>Regional Hypothermia in Combination With Endovascular Thrombectomy in Acute Ischemic Stroke</brief_title>
  <acronym>RE-HIBER</acronym>
  <official_title>Regional Hypothermia in Combination With Endovascular Thrombectomy in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have previous shown that regional hypothermia by the intra-arterial&#xD;
      infusion of cold saline combined with mechanical thrombectomy in acute ischemic stroke is&#xD;
      feasible and safe. The safety of selective brain cooling in patients undergoing mechanical&#xD;
      thrombectomy, however, is not established in a randomized trial. The investigators therefore&#xD;
      conducted this RCT study to further explore the safety of regional hypothermia in patients&#xD;
      with acute ischemic stroke who underwent mechanical thrombectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 16, 2020</start_date>
  <completion_date type="Anticipated">March 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 16, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of any major adverse events</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of intracerebral hemorrhage</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of symptomatic intracerebral hemorrhage</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of death</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS</measure>
    <time_frame>24 hours</time_frame>
    <description>Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final infarct volume</measure>
    <time_frame>5-7 days</time_frame>
    <description>measured on 5-7 days CT (or MRI if available)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS</measure>
    <time_frame>7 days or discharge</time_frame>
    <description>Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin scale</measure>
    <time_frame>90 days</time_frame>
    <description>The modified Rankin scale is a 7-point scale ranging from 0 (no symptoms) to 6 (death). A score of 2 or less indicates functional independence.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of vessel recanalization after treatment</measure>
    <time_frame>24 hours</time_frame>
    <description>Assessed by CTA or MRA</description>
  </other_outcome>
  <other_outcome>
    <measure>The temperature change of the tympanic membrane on the ipsilateral side of the vascular occlusion within one hour after endovascular treatment</measure>
    <time_frame>1 hour</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The patient's rectal temperature within one hour after endovascular treatment</measure>
    <time_frame>1 hour</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Stroke</condition>
  <condition>Neuroprotection</condition>
  <condition>Hypothermia</condition>
  <arm_group>
    <arm_group_label>Regional Hypothermia group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Regional Hypothermia</intervention_name>
    <description>Regional hypothermia was achieved by intraarteral perfusion of cold fluid into the ischemic area of the brain</description>
    <arm_group_label>Regional Hypothermia group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 and ≤80&#xD;
&#xD;
          -  Clinical signs consistent with the diagnosis of an acute ischemic stroke&#xD;
&#xD;
          -  Baseline NIHSS score obtained prior to randomization ≥8&#xD;
&#xD;
          -  Intracranial arterial occlusion of the distal intracranial carotid artery or&#xD;
&#xD;
          -  Middle (M1/M2), demonstrated with CTA, MRA, DSA&#xD;
&#xD;
          -  The possibility to start treatment (artery puncture) within 6 hours from onset&#xD;
&#xD;
          -  Regional hypothermia is expected to start within 15 minutes after recanalization&#xD;
&#xD;
          -  Informed consent given&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  mTICI&lt;2b after endovascular treatment&#xD;
&#xD;
          -  No significant pre-stroke disability (mRS ≤1)&#xD;
&#xD;
          -  Previous NYHA grade &gt; 1&#xD;
&#xD;
          -  Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant&#xD;
             therapy with INR &gt; 3.0&#xD;
&#xD;
          -  Baseline platelet count &lt; 50000/µL&#xD;
&#xD;
          -  Baseline blood glucose of &lt; 50mg/dL or &gt;400mg/dl&#xD;
&#xD;
          -  Severe, sustained hypertension (SBP &gt; 220 mm Hg or DBP &gt; 110 mm Hg). NOTE: If the&#xD;
             blood pressure can be successfully reduced and maintained at the acceptable level&#xD;
             using local treatment guidelines recommended medication (including iv antihypertensive&#xD;
             drips), the patient can be enrolled.&#xD;
&#xD;
          -  Seizures at stroke onset which would preclude obtaining a baseline NIHSS&#xD;
&#xD;
          -  Subjects who have received iv t-PA treatment beyond 4,5 hours from the beginning of&#xD;
             the symptoms&#xD;
&#xD;
          -  Renal insufficiency with creatinine ≥ 3 mg/dl&#xD;
&#xD;
          -  Woman of childbearing potential who is known to be pregnant or lactating&#xD;
&#xD;
          -  Subject participating in a study involving an investigational drug or device that&#xD;
             would impact this study&#xD;
&#xD;
          -  Cerebral vasculitis&#xD;
&#xD;
          -  Patients with a pre-existing neurological or psychiatric disease that would confound&#xD;
             the neurological or functional evaluations&#xD;
&#xD;
          -  Unlikely to be available for 3 months follow-up (e.g. no fixed home address, visitor&#xD;
             from overseas).&#xD;
&#xD;
          -  CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed)&#xD;
&#xD;
          -  ASPECT&lt;6&#xD;
&#xD;
          -  Subjects with occlusions in multiple vascular territories (anterior circulation and&#xD;
             posterior circulation)&#xD;
&#xD;
          -  Evidence of intracranial tumor (except small meningioma)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xunming Ji, MD</last_name>
    <phone>01083199439</phone>
    <email>jixm@ccmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chuanjie Wu, MD</last_name>
    <email>wuchuanjie8557@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xuanwu Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xunming Ji</last_name>
    </contact>
    <investigator>
      <last_name>Xunming Ji</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lu He hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaokun Geng, MD</last_name>
      <phone>18311055270</phone>
      <email>xgeng@ccmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 13, 2020</study_first_submitted>
  <study_first_submitted_qc>September 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Ji Xunming,MD,PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

